Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | CCR3 | P51677 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017233 | 0.83 | MEN1 (0.54) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL7240972 | 0.79 | MAPK1 (0.54) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL7240975 | 0.79 | MAPK1 (0.54) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL6758154 | 0.75 | LTA4H (0.65) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL6758155 | 0.75 | LTA4H (0.65) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL4435207 | 0.75 | KCNH2 (0.50) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL6154470 | 0.74 | KCNH2 (0.65) | KCNH2OPRK1OPRM1OPRD1LTA4H | |
| SCHEMBL7545873 | 0.74 | L3MBTL1 (0.65) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL3527134 | 0.73 | ROCK2 (0.59) | KCNH2OPRK1OPRM1OPRD1MEN1 | |
| SCHEMBL3872086 | 0.73 | SIGMAR1 (0.67) | OPRK1MEN1KMT2ACCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648888-A1 | N-(HETEROBICYCLOALKANES)-SUBSTITUTED INDOLES OR HETERODERIVATIVES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2006-04-26 | — | — | EP | disclosed |
| US-20050014782-A1 | Novel n-(heterobicycloalkanes)-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2005005425-A1 | N-(HETEROBICYCLOALKANES)-SUBTITUTED INDOLES- OR HETERODERIVATIVES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
| EP-1496058-A1 | Novel N-(heterobicycloalkanes)-substituted Indoles or heteroderivatives thereof | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014782-A1 | Novel n-(heterobicycloalkanes)-substituted indoles-or heteroderivatives thereof | CCR3, CCR1, CCRL2 | KCNH2 1153/4885OPRK1 37/4885OPRM1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.